Sugi Predict

Sugi Predict / Compounds / SCHEMBL999536

SCHEMBL999536

SCHEMBL999536

CC(C)(C)OC(=O)NC(C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR3 Q99500 2/20 0.53
▸ CTSS P25774 1/20 0.51
▸ CTSK P43235 1/20 0.51
▸ PPARA Q07869 3/20 0.50
▸ PPARG P37231 2/20 0.50
▸ TRPA1 O75762 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ P2RY2 P41231 1/20 0.41
▸ ATM Q13315 2/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CTSL P07711 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277192 1.00 S1PR3 (0.53) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL4289099 1.00 S1PR3 (0.53) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL31750821 0.88 S1PR3 (0.50) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL1525501 0.87 CACNA1B (0.45) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL1525609 0.87 CACNA1B (0.45) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL1525465 0.87 S1PR3 (0.52) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL1525463 0.87 S1PR3 (0.52) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL1525552 0.87 S1PR3 (0.52) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL8513252 0.86 CTSS (0.52) S1PR3CTSSCTSKPPARAPPARG
SCHEMBL191986 0.86 CTSS (0.52) S1PR3CTSSCTSKPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590087-B2 Inhibiting USP36 VALO HEALTH, INC. (US) 2026-03-31 — — US disclosed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 — — EP disclosed
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 — — WO disclosed
WO-2024224086-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2024-10-31 — — WO disclosed
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
EP-4126876-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS Global Blood Therapeutics, Inc. (US) 2023-02-08 — — EP disclosed
CN-115551864-A Substituted tricyclic amides, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-12-30 — — CN disclosed
US-11407721-B2 CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer AMGEN INC. (US) 2022-08-09 — — US disclosed
US-20220213088-A1 INHIBITING USP36 Valo Health, LLC 2022-07-07 — — US disclosed
US-20220213088-A1 INHIBITING USP36 Valo Health, LLC 2022-07-07 — — US disclosed
CN-101970415-A 5H-cyclopenta [ d ] pyrimidines as AKT protein kinase inhibitors ARRAY BIOPHARMA INC 2011-02-09 — — CN disclosed
EP-2268624-A1 ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2011-01-05 — — EP disclosed
EP-2250155-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-11-17 — — EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 — — WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 — — US disclosed
WO-2009132739-A1 ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-11-05 — — WO disclosed
WO-2009132739-A1 ARYLPYRAZINONE DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-11-05 — — WO disclosed
WO-2009089462-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
US-20090137609-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-05-28 — — US disclosed
EP-1894911-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137609-A1 VITAMIN D-LIKE COMPOUND VDR, CYP24A1, CYP2R1 S1PR3 277/4885CTSS 1699/4885CTSK 885/4885
US-11407721-B2 CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer MDM2, TP53, MDM4 S1PR3 3894/4885CTSS 2469/4885CTSK 2125/4885
US-20220213088-A1 INHIBITING USP36 USP36, USP30, USP39 S1PR3 4629/4885CTSS 3043/4885CTSK 2991/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CTSS 3935/4885CTSK 4555/4885
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM S1PR3 1644/4885CTSS 4325/4885CTSK 2102/4885
US-12590087-B2 Inhibiting USP36 USP36, USP39, USP30 S1PR3 4692/4885CTSS 2261/4885CTSK 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.